Freenome's Updated Blood Test Delivers Best-in-Class Cancer Detection Ahead of SPAC Vote
PCSC is trading near its 52-week low of $10.13 (14% above the low).
Summary
Freenome's updated blood test for colorectal cancer screening achieved best-in-class detection of precancerous lesions in a pivotal study, strengthening the clinical rationale for its SPAC merger with Perceptive Capital Solutions Corp. The shareholder vote was postponed to July 15 to incorporate the new data.
Key Events · Product Development and Regulatory · PCSC
-
Best-in-Class Cancer Detection Data
Freenome's updated SimpleScreen CRC test showed 80.4% sensitivity for colorectal cancer and 18.2% for advanced precancerous lesions (APLs) in a pivotal clinical validation study, with 41.9% sensitivity for APLs with high-grade dysplasia — the highest reported for any non-invasive blood test in a prospective registrational study.
-
Pivotal Study Met Endpoints
The study successfully met its primary and secondary endpoints, using blinded samples from the 48,995-participant PREEMPT CRC registrational trial. Specificity was 90% for no findings on colonoscopy.
-
Merger Vote Postponed to July 15
The extraordinary general meeting to approve the SPAC merger with Freenome has been postponed to July 15, 2026, with the redemption deadline extended to July 13, 2026, to allow shareholders to consider the new clinical data.
-
Improved Patient Outcomes Projected
Modeling suggests the updated test would yield 7.7% more life-years gained, 9.5% more cancers prevented, and 9.5% more cancer deaths prevented compared to the first-generation test.
Analysis · PCSC · Industrial Applications And Services
A pivotal study of Freenome's updated SimpleScreen blood test delivered the highest sensitivity ever reported for a non-invasive screening test — 80.4% for colorectal cancer and 41.9% for advanced precancerous lesions with high-grade dysplasia. These results, disclosed in a proxy supplement that also postpones the SPAC merger vote to July 15, dramatically strengthen the clinical case for the pending business combination. The data beat the prior version and position Freenome as a potential leader in blood-based cancer screening, directly addressing a key risk factor for the merger.
At the time of this filing, PCSC was trading at $11.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $117.6M. The 52-week trading range was $10.13 to $14.47. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.